We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Foundations Fund Fast-Track Development of Ebola Test

By LabMedica International staff writers
Posted on 07 Dec 2014
Print article
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, has announced the award of a grant of up to USD 3.3 million co-financed by the Paul G. Allen Family Foundation and the Bill & Melinda Gates Foundation to quickly develop its “Xpert Ebola” test for use in regions worst hit by the epidemic. Cepheid expects to deliver a prototype in as little as eight weeks.

The initial test is expected to be offered on an emergency-use-only basis. “While we are all hopeful that the Ebola epidemic dissipates quickly, we welcome the opportunity to develop an accurate, rapid, and easy-to-use test with the potential to strengthen the arsenal of tools being deployed to address the current situation,” said John Bishop, Cepheid's chairman and CEO, “Cepheid has historically played a leading role in developing molecular diagnostics as an aid to infection control efforts, and the current Ebola crisis represents an extreme example of the need for sensitive, rapid, and easy-to-use diagnostics to inform patient management and isolation requirements.”

Xpert Ebola could be run on Cepheid's installed base of more than 3,500 automated GeneXpert Systems in developing countries, including more than 1,000 in Africa. More information about its features will be available as the project progresses, but Cepheid currently expects the sample-type to be an oral swab or capillary whole blood specimen in order to avoid needle exposure and venipuncture.

“Cepheid is well positioned to respond quickly to this urgent imperative. We are leveraging our significant investments in development of ultrasensitive HIV and TB detection technologies, and are borrowing on previous experience with an Ebola project to expedite delivery of the initial prototype and emergency-use-only product,” said David Persing, MD, PhD, Cepheid's Chief Medical and Technology Officer, “We expect this technology to facilitate high-throughput testing requirements of Ebola Treatment Units, as well as deployment of mobile laboratories for field surveillance.”

In addition to Xpert Ebola, Cepheid and the Gates Foundation are evaluating deployment of Cepheid's RemoteXpert cloud-based monitoring software, currently implemented for TB testing on a pilot basis in South Africa and India. In the pilot phase, RemoteXpert has collected real-time data streams from nearly 2.5 million cases being evaluated for tuberculosis and drug resistance. RemoteXpert could enable authorized agencies, for the first time, to access real-time testing activity and geopositioned Ebola test results in order to track the spread of the virus and the effectiveness of ongoing efforts to contain it.

Related Links:

Cepheid


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Silver Member
Rubella Infection ELISA
ReQuest RUBELLA IgM ELISA Kit
New
Quantitative Immunoassay Analyzer
AS050

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The FDA clearance for the QIAstat-Dx Respiratory Panel Mini test follows the recent approval of QIAstat-Dx Respiratory Panel Plus (Photo courtesy of QIAGEN)

Respiratory Panel to Help Clinicians Make Precise Treatment Decisions in Outpatient Settings

Respiratory tract infections are the primary reason for visits to emergency departments and subsequent hospitalizations. In the U.S., it is estimated that there are up to 41 million cases of influenza... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image: The new technique allows properties of cancer cells and their surrounding tissue to be analyzed in detail at single-cell level (Photo courtesy of Universität Helsinki/Karolina Punovuori)

New Imaging Method Opens Door to Precision Diagnostics for Head and Neck Cancers

Head and neck cancers, while considered rare, represent a significant portion of cancer cases and have seen a notable increase over the past 30 years. These cancers encompass various malignant tumors that... Read more